News & Media

News & Media

Press releases

February 4, 2019
Kyn Therapeutics Appoints Douglas Carlson as Chief Financial Officer

January 18, 2019
Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene to Develop Immuno-oncology Therapies

December 19, 2018
Kyn Therapeutics Announces Initiation of Phase 1b/2 Clinical Studies of ARY-007 in Collaboration with Merck

March 21, 2018
Kyn Therapeutics Appoints Chairman and Scientific Advisory Board Member

December 14, 2017
Kyn Therapeutics Announces $49 Million Series A Capital Available to Develop Cancer Therapy Candidates with Novel Approaches to Major Immunometabolism Pathways

In the news

Xconomy
Despite Buyout, Celgene Dealmaking Rolls On With Kyn, Obsidian Tie-Ups

Endpoints News
Celgene inks first deals since Bristol-Myers announced $74B buyout — bets $80M on immunometabolism

Boston Business Journal
Ahead of Bristol Myers purchase, Celgene partners with Boston cancer startup

Bloomberg
Bloomberg Baystate Business: Biogen, Budget and ESG

view all Tweets

Twitter

@KynTherapeutics
Looking to learn about the research unfolding in #immunometabolism? Our website lists publications from Kyn team me… http://4NY4mxCe5n

@KynTherapeutics
Our team is growing and we're seeking enthusiastic new colleagues who want to help us open new areas of #cancer the… http://dqC9HAmBGi

@KynTherapeutics
Art and science enhance each other. Our Seaport office embodies this fact, thanks to the beautiful work from local… http://ph5K0Okujj

@KynTherapeutics
#MeetTheTeam: Our CEO @markgmanfredi is an avid runner who often joins group workouts with our @atlasventure collea… http://UH2zWEVsG1

Corporate fact sheet

download now

Media contact

Tom Donovan
Ten Bridge Communications
857-559-3397
tom@tenbridgecommunications.com

Alerts

Sign up to get up-to-date news about Kyn Therapeutics.

Contact us

Find us

Kyn Therapeutics
50 Northern Avenue
7th Floor
Boston, MA 02210

Call us

1-857-273-8343

Email us

info@kyntherapeutics.com

Friend us

LinkedIn